Literature DB >> 19049325

FGF2 stimulation of the pyrophosphate-generating enzyme, PC-1, in pre-osteoblast cells is mediated by RUNX2.

Nan E Hatch1, Yan Li, Renny T Franceschi.   

Abstract

Pyrophosphate is an established inhibitor of hydroxyapatite deposition and crystal growth, yet when hydrolyzed into phosphate, it becomes a substrate for hydroxyapatite deposition. Pyrophosphate-generating enzyme (PC-1), Ank, and tissue nonspecific alkaline phosphatase (Tnap) are three factors that regulate extracellular pyrophosphate levels through its generation, transport, and hydrolysis. We previously showed that fibroblast growth factor 2 (FGF2) induces PC-1 and Ank while inhibiting Tnap expression and mineralization in MC3T3E1(C4) calvarial pre-osteoblast cells. In this study, we showed similar FGF2 regulation of these genes in primary pre-osteoblast cultures. In contrast to Ank and Tnap that are regulated by FGF2 in multiple cell types, we found regulation of PC-1 to be selective to pre-osteoblastic cells and to require the osteoblast-related transcription factor, Runx2. Specifically, FGF2 was unable to induce PC-1 expression in Runx2-negative nonbone cells or in calvarial cells from Runx2-deficient mice. Transfection of these cells with a Runx2 expression vector restored FGF2 responsiveness. FGF2 was also shown to stimulate recruitment of Runx2 to the endogenous PC-1 promoter in MC3T3E1(C4) cells, as measured by chromatin immunoprecipitation. Taken together, our results establish that FGF2 is a specific inducer of PC-1 in pre-osteoblast cells and that FGF2 induces PC-1 expression through a mechanism involving Runx2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19049325      PMCID: PMC2659512          DOI: 10.1359/jbmr.081213

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  37 in total

1.  Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK.

Authors:  E Reichenberger; V Tiziani; S Watanabe; L Park; Y Ueki; C Santanna; S T Baur; R Shiang; D K Grange; P Beighton; J Gardner; H Hamersma; S Sellars; R Ramesar; A C Lidral; A Sommer; C M Raposo do Amaral; R J Gorlin; J B Mulliken; B R Olsen
Journal:  Am J Hum Genet       Date:  2001-04-16       Impact factor: 11.025

2.  Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia.

Authors:  P Nürnberg; H Thiele; D Chandler; W Höhne; M L Cunningham; H Ritter; G Leschik; K Uhlmann; C Mischung; K Harrop; J Goldblatt; Z U Borochowitz; D Kotzot; F Westermann; S Mundlos; H S Braun; N Laing; S Tinschert
Journal:  Nat Genet       Date:  2001-05       Impact factor: 38.330

3.  Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.

Authors:  Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

4.  The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2.

Authors:  Hyun-Jung Kim; Jung-Hwan Kim; Suk-Chul Bae; Je-Yong Choi; Hyun-Jung Kim; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2002-10-25       Impact factor: 5.157

5.  Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats.

Authors:  H Liang; S Pun; T J Wronski
Journal:  Endocrinology       Date:  1999-12       Impact factor: 4.736

6.  Mutations in ANKH cause chondrocalcinosis.

Authors:  Adrian Pendleton; Michelle D Johnson; Anne Hughes; Kyle A Gurley; Andrew M Ho; Michael Doherty; Josh Dixey; Pierre Gillet; Damien Loeuille; Rodney McGrath; Antonio Reginato; Rita Shiang; Gary Wright; Patrick Netter; Charlene Williams; David M Kingsley
Journal:  Am J Hum Genet       Date:  2002-09-20       Impact factor: 11.025

7.  Role of the mouse ank gene in control of tissue calcification and arthritis.

Authors:  A M Ho; M D Johnson; D M Kingsley
Journal:  Science       Date:  2000-07-14       Impact factor: 47.728

8.  Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1.

Authors:  K A Johnson; L Hessle; S Vaingankar; C Wennberg; S Mauro; S Narisawa; J W Goding; K Sano; J L Millan; R Terkeltaub
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-10       Impact factor: 3.619

9.  Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2.

Authors:  Guozhi Xiao; Di Jiang; Rajaram Gopalakrishnan; Renny T Franceschi
Journal:  J Biol Chem       Date:  2002-08-28       Impact factor: 5.157

10.  Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization.

Authors:  Lovisa Hessle; Kristen A Johnson; H Clarke Anderson; Sonoko Narisawa; Adnan Sali; James W Goding; Robert Terkeltaub; José Luis Millan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-24       Impact factor: 11.205

View more
  15 in total

1.  Ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) protein regulates osteoblast differentiation.

Authors:  Hwa Kyung Nam; Jin Liu; Yan Li; Andrew Kragor; Nan E Hatch
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

2.  ERK acts in parallel to PKCδ to mediate the connexin43-dependent potentiation of Runx2 activity by FGF2 in MC3T3 osteoblasts.

Authors:  Corinne Niger; Atum M Buo; Carla Hebert; Brian T Duggan; Mark S Williams; Joseph P Stains
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

Review 3.  Calcium and bone disease.

Authors:  Harry C Blair; Lisa J Robinson; Christopher L-H Huang; Li Sun; Peter A Friedman; Paul H Schlesinger; Mone Zaidi
Journal:  Biofactors       Date:  2011-06-14       Impact factor: 6.113

4.  Craniosynostosis, psychomotor retardation, and facial dysmorphic features in a Spanish patient with a 4q27q28.3 deletion.

Authors:  Alberto Fernández-Jaén; Ana Laura Fernández-Perrone; Daniel Martín Fernández-Mayoralas; Beatriz Calleja-Pérez; María Del Carmen Sánchez-Hombre; Ester Corbacho Fernández; Sara López-Martín
Journal:  Childs Nerv Syst       Date:  2014-07-01       Impact factor: 1.475

5.  Further analysis of the Crouzon mouse: effects of the FGFR2(C342Y) mutation are cranial bone-dependent.

Authors:  Jin Liu; Hwa Kyung Nam; Estee Wang; Nan E Hatch
Journal:  Calcif Tissue Int       Date:  2013-01-29       Impact factor: 4.333

6.  The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts.

Authors:  Nadiya M Teplyuk; Larisa M Haupt; Ling Ling; Christian Dombrowski; Foong Kin Mun; Saminathan S Nathan; Jane B Lian; Janet L Stein; Gary S Stein; Simon M Cool; Andre J van Wijnen
Journal:  J Cell Biochem       Date:  2009-05-01       Impact factor: 4.429

7.  Enzyme replacement for craniofacial skeletal defects and craniosynostosis in murine hypophosphatasia.

Authors:  Jin Liu; Cassie Campbell; Hwa Kyung Nam; Alexandre Caron; Manisha C Yadav; José Luis Millán; Nan E Hatch
Journal:  Bone       Date:  2015-05-08       Impact factor: 4.398

8.  The effects of tissue-non-specific alkaline phosphatase gene therapy on craniosynostosis and craniofacial morphology in the FGFR2C342Y/+ mouse model of Crouzon craniosynostosis.

Authors:  E Wang; H K Nam; J Liu; N E Hatch
Journal:  Orthod Craniofac Res       Date:  2015-04       Impact factor: 1.826

9.  Comparison of Osteogenic Potential of Phenytoin with Dexamethasone in Cultured Dental Pulp Stem Cells.

Authors:  Mitra Asgharian-Rezaee; Raheleh Alipour-Farmad; Zahra Tayarani-Najaran
Journal:  Rep Biochem Mol Biol       Date:  2020-10

10.  Craniosynostosis-associated Fgfr2(C342Y) mutant bone marrow stromal cells exhibit cell autonomous abnormalities in osteoblast differentiation and bone formation.

Authors:  J Liu; T-G Kwon; H K Nam; N E Hatch
Journal:  Biomed Res Int       Date:  2013-05-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.